- Syndax Pharmaceuticals is a cancer-focused biotechnology company.
- IPO issue price of $12.
- Syndax sold 4.4 million shares to raise $52.8 million.
- The company had previously set a price range of $14 to $16. Morgan Stanley, Citigroup, JMP Securities and Oppenheimer were the underwriters for the offering.
monthly; Dec 2016; 9 months after IPO
March 2017; 1 year after IPO
Description
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Address
400 Totten Pond Rd Ste 110
WALTHAM, MA 02451-2040
United States
WALTHAM, MA 02451-2040
United States
Key stats and ratios
| Q4 (Dec '16) | 2016 | |
| Net profit margin | -3545.90% | -3645.25% |
| Operating margin | -3652.79% | -3587.38% |
| EBITD margin | - | -3580.08% |
| Return on average assets | -38.26% | -44.71% |
| Return on average equity | -48.75% | - |
| Employees | 17 |
No comments:
Post a Comment